tetano
Editor, Senior Moderator
Expert Rev Anti Infect Ther
. 2021 Mar 1;1-8.
doi: 10.1080/14787210.2021.1878025. Online ahead of print.
Comparing intravenous peramivir with oral oseltamivir for patients with influenza: a meta-analysis of randomized controlled trials
Yu-Hsing Fang[SUP] 1 [/SUP], Tzu-Herng Hsu[SUP] 2 3 [/SUP], Tzu-Yin Lin[SUP] 1 [/SUP], Chia-Hung Liu[SUP] 1 4 [/SUP], Shou-Chu Chou[SUP] 1 [/SUP], Jie-Ying Wu[SUP] 1 [/SUP], Pang-Chung Perng[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The study was to compare the efficacy between IV peramivir and oral oseltamivir treatments in patients with influenza.Methods: The PubMed, EMBASE, Scopus, ClinicalTrials.gov, and Cochrane Library databases were searched for studies published before January 2020.Results: The meta-analysis was conducted to calculate the pooled effect size by using a random-effects model. Seven randomized controlled trials (RCTs) including 1,138 patients were reviewed. The incidence of total complications revealed no significant difference between 600 mg IV peramivir (P600) and 75 mg oral oseltamivir (O75) treatments (2.8% vs. 4.1%; risk ratio [RR] = 0.70; 95% confidence interval [CI]: 0.36-1.38). The incidence of pneumonia was not significantly different between the P600 and O75 treatment groups (2.2% vs. 2.7%; RR = 0.74; 95% CI: 0.37-1.51). Regarding the time to the alleviation of symptoms, no difference was found in P600 and O75 treatment (MD = -3.00; 95% CI: -11.07 to 5.06). The rate of fever clearance in 24 h and the time to fever resolution were not statistically different between the IV peramivir and oral oseltamivir treatments (at different dosages) groups.Conclusions: The treatment of influenza with IV peramivir or oral oseltamivir had similar clinical efficacy.
Keywords: Influenza; meta-analysis; oseltamivir; peramivir.
. 2021 Mar 1;1-8.
doi: 10.1080/14787210.2021.1878025. Online ahead of print.
Comparing intravenous peramivir with oral oseltamivir for patients with influenza: a meta-analysis of randomized controlled trials
Yu-Hsing Fang[SUP] 1 [/SUP], Tzu-Herng Hsu[SUP] 2 3 [/SUP], Tzu-Yin Lin[SUP] 1 [/SUP], Chia-Hung Liu[SUP] 1 4 [/SUP], Shou-Chu Chou[SUP] 1 [/SUP], Jie-Ying Wu[SUP] 1 [/SUP], Pang-Chung Perng[SUP] 1 [/SUP]
Affiliations
- PMID: 33641583
- DOI: 10.1080/14787210.2021.1878025
Abstract
Background: The study was to compare the efficacy between IV peramivir and oral oseltamivir treatments in patients with influenza.Methods: The PubMed, EMBASE, Scopus, ClinicalTrials.gov, and Cochrane Library databases were searched for studies published before January 2020.Results: The meta-analysis was conducted to calculate the pooled effect size by using a random-effects model. Seven randomized controlled trials (RCTs) including 1,138 patients were reviewed. The incidence of total complications revealed no significant difference between 600 mg IV peramivir (P600) and 75 mg oral oseltamivir (O75) treatments (2.8% vs. 4.1%; risk ratio [RR] = 0.70; 95% confidence interval [CI]: 0.36-1.38). The incidence of pneumonia was not significantly different between the P600 and O75 treatment groups (2.2% vs. 2.7%; RR = 0.74; 95% CI: 0.37-1.51). Regarding the time to the alleviation of symptoms, no difference was found in P600 and O75 treatment (MD = -3.00; 95% CI: -11.07 to 5.06). The rate of fever clearance in 24 h and the time to fever resolution were not statistically different between the IV peramivir and oral oseltamivir treatments (at different dosages) groups.Conclusions: The treatment of influenza with IV peramivir or oral oseltamivir had similar clinical efficacy.
Keywords: Influenza; meta-analysis; oseltamivir; peramivir.